RGLS - Regulus Therapeutics Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.1968
-0.0123 (-5.88%)
As of 1:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.2091
Open0.2100
Bid0.1941 x 1300
Ask0.1970 x 3200
Day's Range0.1926 - 0.2162
52 Week Range0.1700 - 1.5200
Volume485,072
Avg. Volume1,382,122
Market Cap20.632M
Beta1.59
PE Ratio (TTM)N/A
EPS (TTM)-0.5970
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.50
Trade prices are not sourced from all markets
  • Do You Know Who Else Invests In Regulus Therapeutics Inc (NASDAQ:RGLS)?
    Simply Wall St.5 days ago

    Do You Know Who Else Invests In Regulus Therapeutics Inc (NASDAQ:RGLS)?

    The big shareholder groups in Regulus Therapeutics Inc (NASDAQ:RGLS) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning aRead More...

  • ACCESSWIRElast month

    These Biotech Stocks Are Moving Higher in August

    GT Biopharma (GTBP) for example, recently announced that the company has a Material Transfer Agreement between a Major Pharmaceutical Company and Dr. Daniel Vallera, Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota, has brought some attention to the company. Under the terms of the agreement, this Company will supply a formulation of their multibillion-dollar, widely prescribed oncology drug, which has been approved for use in several hematologic malignancies to Dr. Vallera to be used in this study.

  • Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates

    Regulus (RGLS) delivered earnings and revenue surprises of 18.75% and -10.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Regulus: 2Q Earnings Snapshot

    The San Diego-based company said it had a loss of 13 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for ...

  • Regulus Reports Second Quarter 2018 Financial Results and Recent Updates
    PR Newswire2 months ago

    Regulus Reports Second Quarter 2018 Financial Results and Recent Updates

    Corporate Restructuring and Pipeline Focus Expected to Extend Cash Runway Amendment to Term Loan to Provide Additional Interest-Only Period LA JOLLA, Calif. , Aug. 9, 2018 /PRNewswire/ --  Regulus Therapeutics ...

  • Regulus Stock Plunges on Cash Concerns Despite Restructuring
    Zacks3 months ago

    Regulus Stock Plunges on Cash Concerns Despite Restructuring

    Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.

  • Regulus Announces Strategic Update and Corporate Restructuring
    PR Newswire3 months ago

    Regulus Announces Strategic Update and Corporate Restructuring

    Efforts Aimed at Extending Cash Runway to mid-2019 LA JOLLA, Calif. , July 5, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development ...

  • ACCESSWIRE3 months ago

    Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities

    Stock Research Monitor: RGNX, RGLS, and ABEO LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on XXII sign up now at www.wallstequities.com/registration . For today, WallStEquities.com ...

  • Gaithersburg biotech raising $1M to stop cancer tumors in their tracks
    American City Business Journals3 months ago

    Gaithersburg biotech raising $1M to stop cancer tumors in their tracks

    Key story highlights: Gaithersburg-based miRecule Inc., which is developing therapeutics for cancers that become drug-resistant, is raising $1 million in seed funding. CEO Anthony Saleh spun the company out of the National Institutes of Health in 2016. Long term, Saleh plans to license its technology to pharmaceutical companies.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of RGLS earnings conference call or presentation 10-May-18 9:00pm GMT

    Q1 2018 Regulus Therapeutics Inc Earnings Call

  • Associated Press5 months ago

    Regulus: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 15 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress
    PR Newswire5 months ago

    Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress

    Two pre-clinical programs advance towards clinical candidates Conference call today at 5:00 p.m. ET LA JOLLA, Calif. , May 10, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical ...

  • Regulus to Provide First Quarter 2018 Financial Results on May 10, 2018
    PR Newswire5 months ago

    Regulus to Provide First Quarter 2018 Financial Results on May 10, 2018

    Regulus will host a conference call and webcast on May 10, 2018 at 5:00pm Eastern Time to discuss first quarter 2018 financial results and provide a general business update.  A live webcast of the call will be available online at www.regulusrx.com.  To access the call, please dial (877) 257-8599 (domestic) or (970) 315-0459 (international) and refer to conference ID 8993969. To access the replay of the call, dial (855) 859-2056 (domestic) or (404) 537-3406 (international), conference ID 8993969. Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting microRNAs to treat diseases with significant unmet medical need.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic, and central nervous systems diseases.

  • Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD
    PR Newswire5 months ago

    Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD

    LA JOLLA, Calif., May 1, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has initiated a Phase I multiple ascending dose (MAD) study in healthy volunteers for RGLS4326 for the treatment of autosomal dominant polycystic kidney disease, or ADPKD. "We are pleased to advance the RGLS4326 program with the initiation of the MAD study, which will allow us to further characterize the safety and pharmacokinetic profile of RGLS4326 and establish the dose range that we will study in patients with ADPKD," said Timothy Wright, M.D., Chief R&D Officer of Regulus.

  • Kathryn J. Collier Joins Regulus Board of Directors
    PR Newswire5 months ago

    Kathryn J. Collier Joins Regulus Board of Directors

    LA JOLLA, Calif., April 17, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced Kathryn J. Collier has joined the Company's board of directors. "I am honored to join the Regulus board and look forward to bringing my strategic, financial, and operational experience and expertise to serve Regulus' board and management," said Kate Collier.

  • Regulus to Present at the Needham Healthcare Conference
    PR Newswire6 months ago

    Regulus to Present at the Needham Healthcare Conference

    Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of RGLS earnings conference call or presentation 7-Mar-18 10:00pm GMT

    Q4 2017 Regulus Therapeutics Inc Earnings Call

  • Associated Press7 months ago

    Regulus reports 4Q loss

    The San Diego-based company said it had a loss of 14 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for ...

  • Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update
    PR Newswire7 months ago

    Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update

    Full enrollment of RG-012 studies anticipated in 2H 2018 RGLS4326 Phase I study on track Conference call today at 5:00 p.m. ET LA JOLLA, Calif. , March 7, 2018 /PRNewswire/ -- Regulus Therapeutics Inc ...

  • ACCESSWIRE7 months ago

    Regulus Therapeutics Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Regulus Therapeutics Inc. (NASDAQ: RGLS ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018, at 5:00 PM Eastern ...

  • Was Regulus Therapeutics Inc’s (NASDAQ:RGLS) Earnings Decline A Part Of Broader Industry Downturn?
    Simply Wall St.7 months ago

    Was Regulus Therapeutics Inc’s (NASDAQ:RGLS) Earnings Decline A Part Of Broader Industry Downturn?

    When Regulus Therapeutics Inc (NASDAQ:RGLS) announced its most recent earnings (30 September 2017), I did two things: looked at its past earnings track record, then look at what is happeningRead More...

  • Regulus to Present at the Cowen and Company 38th Annual Health Care Conference
    PR Newswire7 months ago

    Regulus to Present at the Cowen and Company 38th Annual Health Care Conference

    A live webcast of the presentation can be accessed on the Investors page of the Regulus website at www.regulusrx.com.  An archived replay of the webcast will be available on the Company's website after the conference. Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic and central nervous systems diseases.